New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pamidronic acid 26mg equivalent to 30.9 mg pamidronic acid disodium - powder for injection - 30 mg - active: pamidronic acid 26mg equivalent to 30.9 mg pamidronic acid disodium excipient: mannitol phosphoric acid sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pamidronic acid 51.96mg equivalent to 61.74 mg pamidronic acid disodium;   - powder for injection - 60 mg - active: pamidronic acid 51.96mg equivalent to 61.74 mg pamidronic acid disodium   excipient: mannitol phosphoric acid sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - pamidronic acid 78.05mg equivalent to 92.75 mg pamidronic acid disodium - powder for injection - 90 mg - active: pamidronic acid 78.05mg equivalent to 92.75 mg pamidronic acid disodium excipient: mannitol phosphoric acid sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pamidronic acid 2.53 mg/ml equivalent to 3 mg/ml pamidronate disodium - concentrate for injection - 3 mg/ml - active: pamidronic acid 2.53 mg/ml equivalent to 3 mg/ml pamidronate disodium excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominately lytic bone metastases from breast cancer and advanced multiple myeloma · acute management of tumour induced hypercalcaemia (hypercalcaemia of malignancy) · treatment of symptomatic paget's disease of the bone.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pamidronic acid 5.05 mg/ml equivalent to 6 mg/ml pamidronate disodium - concentrate for injection - 6 mg/ml - active: pamidronic acid 5.05 mg/ml equivalent to 6 mg/ml pamidronate disodium excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominately lytic bone metastases from breast cancer and advanced multiple myeloma · acute management of tumour induced hypercalcaemia (hypercalcaemia of malignancy) · treatment of symptomatic paget's disease of the bone.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - pamidronic acid 7.58 mg/ml equivalent to 9 mg/ml pamidronate disodium - concentrate for injection - 9 mg/ml - active: pamidronic acid 7.58 mg/ml equivalent to 9 mg/ml pamidronate disodium excipient: mannitol phosphoric acid sodium hydroxide water for injection - treatment of conditions associated with increased osteoclast activity: · predominately lytic bone metastases from breast cancer and advanced multiple myeloma · acute management of tumour induced hypercalcaemia (hypercalcaemia of malignancy) · treatment of symptomatic paget's disease of the bone.

Namibia - English - Namibia Medicines Regulatory Council

cipla - medpro (pty) ltd - pamidrone disodium - injection - each 10 ml of injection vial contains pamidronate disodium equivalent to palmidronic acid 90 mg

Namibia - English - Namibia Medicines Regulatory Council

cipla - medpro (pty) ltd - pamidrone disodium - injection - each 10 ml of injection vial contains pamidronate disodium equivalent to palmidronic acid 60 mg

Namibia - English - Namibia Medicines Regulatory Council

cipla - medpro (pty) ltd - pamidrone disodium - injection - each 10 ml of injection vial contains pamidronate disodium equivalent to palmidronic acid 30 mg

Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharmaceuticals europe b.v. - pamidronic acid - concentrate for soln for inf - 3 mg/ml